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Abstract
We studied whether celiac disease (CD) patients produce antibodies against a novel gliadin peptide specifically
generated in the duodenum of CD patients by a previously described pattern of CD-specific duodenal proteases.
Fingerprinting and ion-trap mass spectrometry of CD-specific duodenal gliadin-degrading protease pattern revealed a
new 8-mer gliadin-derived peptide. An ELISA against synthetic deamidated 8-mer peptides (DGP 8-mer) was used to
study the presence of IgA anti-DGP 8-mer antibodies in plasma samples from 81 children (31 active CD patients
(aCD), 17 CD patients on a gluten-free diet (GFD), 10 healthy controls (C) and 23 patients with other gastrointestinal
pathology (GP)) and 101 adults (16 aCD, 12 GFD, 27 C and 46 GP-patients). Deamidation of the 8-mer peptide
significantly increased the reactivity of the IgA antibodies from CD patients against the peptide. Significant IgA anti-
DGP 8-mer antibodies levels were detected in 93.5% of aCD-, 11.8% of GFD- and 4.3% of GP-patients in children. In
adults, antibodies were detected in 81.3% of aCD-patients and 8.3% of GFD-patients while were absent in 100% of
C- and GP-patients. Duodenal CD-specific gliadin degrading proteases release an 8-mer gliadin peptide that once
deamidated is an antigen for specific IgA antibodies in CD patients which may provide a new accurate diagnostic tool
in CD.
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Introduction
Celiac disease (CD) is a gluten-sensitive enteropathy that
develops in genetically susceptible individuals following
exposure to dietary wheat gluten and similar proteins from
barley, rye and some varieties of oats [1–3] (Highlights S1).
Prolamins constitute eighty percent of total gluten proteins.
They are soluble in ethanol and rich in glutamine (Q) and
proline (P) residues. Their names varies based on the source
cereal (gliadin from wheat, secalin from rye, hordein from
barley and avenin from oats) and they are classified in α-, γ-
and ω-prolamins according to their electrophoretic mobility.
The remaining 20% of the total gluten proteins are insoluble in
ethanol and are divided in high molecular weight (HMW) and
low molecular weight (LMW) glutenins.
CD is characterized by villous atrophy, crypt hyperplasia and
infiltration of inflammatory cells, both in the epithelium and in
the mucosal lamina propria of the small intestine. The disease
might affect approximately 1% of the Caucasian population. At
present, the only treatment for CD is a life-long strict gluten-
free diet (GFD), which in most cases leads to a complete
remission of the disease.
The inflammatory reaction appears to be driven by activation
of Th1-like-CD4+ T cells that recognize gluten peptides
modified by the enzyme tissue transglutaminase (tTG) in the
context of human histocompatibility leucocyte antigen (HLA)
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region namely the HLA-DQ2/DQ8 molecules [4,5]. Deamidation
is important for binding of gliadin-derived peptides to HLA
DQ2/DQ8 molecules and subsequently for the stimulation of T
cells [4]. Several gliadin-derived peptides have been identified
as ligands for the disease-associated HLA-DQ molecules [6].
Whereas the T cell response in CD is relatively well
understood, less is known about the B cell response [7].
Mucosal B cells are triggered to produce antibodies against
food antigens, anti-gliadin (AGA), anti-deamidated gliadin
peptides (DGP); and against self molecules as tTG. At the
mucosal compartments humoral responses are mainly
mediated by IgA antibodies so they are more specific than IgG
antibodies as serological markers in gastrointestinal diseases
like CD.
The diagnosis of CD is based on 3 pillars: i) mucosal
alterations as determined by histological evaluation of
duodenal biopsy, ii) genetic susceptibility (HLA-DQ2/DQ8) and
iii) a positive serology (antibodies against tTG and anti-
endomisium) [8]. Despite small bowel biopsy is still the gold
standard for CD diagnosis, endoscopy is uncomfortable and
expensive. Therefore, research has been focused on
developing less-invasive markers for its correct diagnosis.
Many approaches have led to the identification of several
gluten peptides that can stimulate T cells from CD patients.
Such peptides were found in α-, γ- and ω-gliadins as well as in
glutenins. While α- and ω-gliadin-derived peptides are
immunodominant in adults, responses to the LMW glutenins
and γ-gliadins are frequently observed in children [9,10]. The
study however of gliadin-derived peptides specifically
generated in the duodenum of CD patients improves our
current knowledge about gluten peptides since they may be
used for development of specific serological markers with a
clinical application and/or to target them in vivo to prevent their
immunogenic properties in the celiac duodenum.
We have previously described for the first time to our
knowledge a specific pattern of gliadin-degrading
metalloproteases in the duodenal mucosa of CD patients, not
found in the duodenum from non-CD patients [11]. Therefore
CD patients (both aCD and GFD-patients) who have gliadin
intolerance, carry CD-specific duodenal gliadin-degrading
proteases suggesting a potential implication for such enzymes
in CD pathogenesis.
The origin of the gliadin-degrading activity in CD is still
unknown. One of the most accepted hypothesis is the possible
contribution of specific CD mucosal-associated bacteria [11]
which could be explained by the differences in the microbiota
from patients with active celiac disease and on a GFD reported
recently [12].
In order to study the possible implication of these proteases,
independently of their origin, in the development of CD, here
we studied whether a 8-mer gliadin peptide released by the
action of duodenal CD-specific gliadin-degrading proteases
could be specific epitopes of IgA antibodies found in the
plasma of CD patients. We also studied if deamidation of the 8-
mer gliadin peptide increased its reactivity against the IgA Abs
and if the latter were altered in CD patients following a GFD.
In this manuscript we report for the first time to our
knowledge an 8-mer gliadin-derived peptide specifically
generated in the CD duodenum, that likely deamidated by tTG,
is an epitope of specific IgAs found in plasma samples from CD
patients, providing a potential utility as diagnostic biomarkers
and/or markers to monitor GFD compliance.
Material and Methods
1: Study patients
Four groups of patients have been included in this study:
active CD-patients (aCD), CD-patients on a gluten-free diet
(GFD), healthy controls (C) and patients with other
gastrointestinal pathology (GP). The first one (aCD) included
celiac patients with a recent diagnosis of the disease, therefore
on a normal gluten-containing diet. They had clinical
symptoms, positive serology (IgA anti-TGt and/or IgA anti-
endomisium (EmA) antibodies), genetic susceptibility (HLA-
DQ2/DQ8) and all but one had compatible lesion in the
duodenal biopsy (Marsh I-III). Remainder cases fulfilled the
ESPGHAN criteria (2012) to avoid intestinal biopsy. Celiac
patients on a gluten-free diet (GFD), presented a reduction of
symptoms, a normalization of the serological markers and a
recovery of the histological lesion. Patients with other
gastrointestinal pathology (PGI) were patients with a clinical
profile compatible with CD but where diagnosis was later
discarded, suffering another intestinal disease. These patients
had negative serology and mild mucosal alterations non
compatibles with CD. Finally, a group of healthy controls was
included. Among each study group, patients were separated
according to the age in adults (mean age 35) and children
(mean age 7).
Tissue and plasma samples included in this retrospective
study (2004-2012) were obtained from the Gastroenterology
and Pediatric Services from the Hospital Clínico Universitario
and the Hospital Universitario Rio Hortega, Valladolid, Spain.
Written consent was obtained from adult patients and parents
or legal tutors from children. The study protocol was approved
by the Ethics Committee of both, the Hospital Clínico
Universitario and the Faculty of Medicine, University of
Valladolid.
Biopsy samples.  tissue samples (Table 1) were obtained
according to the revised ESPGHAN criteria [13] from aCD-
patients (n=2), GFD-patients (n=2) and GP-patients (n=2). All
groups included one child and one adult. Duodenal explants
were immediately submerged in 0.5 ml of RNALater® solution
(Ambion Inc, Texas, USA) and stored at -20°C until protein
extraction.
Plasma samples.  Plasma samples were obtained from
blood samples treated with EDTA and were obtained according
to the same inclusion criteria than tissue samples. Plasma
samples (Table 2) were collected from 81 children [31 aCD-
patients, 17 GFD-patients, 10 C-individuals and 23 GP-
patients] and from 101 adults [16 aCD-patients, 12 GFD-
patients, 27 C-individuals and 46 GP-patients], In all cases
plasma samples were immediately stored at -20°C until tested.
2: HLA Genotyping
Genomic DNA was purified from whole blood (UltraClean®
Blood DNA Isolation Kit, Mo Bio, California, USA) and HLA-
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DQ2 genotyping performed by PCR amplification using
sequence specific primers (MWG Biotech, Ebersberg,
Germany) and the Kapa Taq kit (Kapa Biosystems, Boston,
USA) [14]. Analysis of HLA-DQ8 haplotype was only performed
in those DQ2 negative patients, using the DQB1 Only
SSP2LQB1 kit (Micro SSPTM DNA Typing Trays, One Lambda
InC, California, USA).
Table 1. Patients groups from biopsy samples included in
this study according to revised ESPGHAN criteria.
 
Study
patients n Children  Adults  
HLA
DQ2/D
Q8
IgA-
tTG/EM
A
Atrophy
grade at
diagnosis
(Marsh
criteria)
Celiac
patients
aCD-
patient 2 1 1 + + II-III
 GFD-patient 2 1 1 + + II-III
Non-
Celiac
patients
GP-
patient 2 1 1 +/- - (*) M.M
Active celiac disease (aCD-patients), celiac disease on a gluten-free diet (GFD-
patients), healthy controls (C-individuals) and other gastrointestinal pathology (GP-
patients).and (B) plasma samples.
(*). Serological test were performed only in genetically susceptible patients.
M.M = Mild mucosal alterations non compatibles with CD.
doi: 10.1371/journal.pone.0080982.t001
Table 2. Patients groups from plasma samples included in
this study according to revised ESPGHAN criteria.
 
Study
patients n Children  Adults  
HLA
DQ2/D
Q8
IgA-
tTG/E
MA
Atrophy
grade at
diagnosis
(Marsh
criteria)
Celiac
patients aCD-patient 47 31 16 + + II-III
 GFD-patient 29 17 12 + + II-III
Non-
Celiac
patients
C-individual 37 10 27 +/- - (*) N.D
 GP-patient 69 23 46 +/- - (*) N.D/M.M
Active celiac disease (aCD-patients), celiac disease on a gluten-free diet (GFD-
patients), healthy controls (C-individuals) and other gastrointestinal pathology (GP-
patients).
(*). Serological test were performed only in genetically susceptible patients.
N.D = Not determined.
M.M = Mild mucosal alterations non compatibles with CD.
doi: 10.1371/journal.pone.0080982.t002
3: IgA-tTG antibodies
IgA-tTG Abs levels were analyzed in plasma samples by the
available comercial kit (EliA CeliKey IgA, Phadia, Madrid,
Spain) using an UniCAP 100Є Instrument Version 1.0
(Pharmacia Diagnostics AB, Uppsala, Sweden).
4: Zymogram analysis
Proteins from biopsy samples were isolated using the Trizol
Reagent (Applied Biosystems, California, USA) according to
the manufacturer’s protocol and quantified by the Bradford
reaction. A total of 8 µg of protein samples were subsequently
separated in 15% acrilamide/bisacrilamide (37.5:1) gel
electrophoresis gliadin zymograms containing 0.1% of protein
(gliadin, Sigma-Aldrich, Missouri, USA) using a mini-Protean II
system (BioRad Laboratories Inc, California, USA). Gels were
then washed twice (t=15’ each) with 2.5% Triton-X-100 to
remove SDS and allow protein renaturalization, and incubated
overnight at 37°C with the reaction buffer (50 mM Tris, 5 mM
CaCl2, pH 7.5). Protease activity was revealed by staining with
0.1% Coomassie Brilliant Blue R-250 (Bio-Rad, California,
USA) in a mixture of acetic acid:methanol:water (1:3:6), and
destaining in the same solution mixture without the dye. A
molecular weight marker was loaded in every gel
(Kaleidoscope pre-stained standard, BioRad, California, USA).
Additionally, stacking gel was kept during all the process since
the lack of staining, compared to the running gel, was used as
an internal control. All samples were separated at 200 Volts for
50 min in the running gel.
5: Fingerprinting and ion-trap Mass Spectometry
Duodenal CD specific proteases (26 and 82 kDa) from a
previously described gliadin-degrading pattern [11] were
removed from the substrate gel after electrophoresis and
analyzed by a combined fingerprinting using a MALDI-TOF
Reflex™ IV Bruker (Bruker-Franzen Analytic GmbH, Bremen,
Germany) and ion-trap MS on a 3000plus (Bruker Daltonics,
Bremen, Germany) coupled to a Famos-Switchos-Ultimate
(LCPackings, Amsterdam, The Netherlands) chromatographic
system.
6: Protein and peptide sequence analysis
Protein identification was carried out by searching in the
database of the National Center for Biotechnology Information
(NCBI) using BLASTP algorithm v.2.2.20. Merops peptidase
database (v 9.8) was used to analyze the cleaving points of the
identified peptides.
7: Synthesis of peptides
Different peptides (native and deamidated) and terminal
modifications (i.e. biotinylated peptides) derived from gliadin 8-
mer sequence (Table 3) were supplied by Biomedal SL
(Seville, Spain).
8: Enzyme-linked immunosorbent assay (ELISA)
Maxisorp microtitre plates (Nunc, Roskilde, Denmark) were
coated with a mix of 2 synthetic peptides (Biomedal SL, Spain)
in phosphate buffer (pH 7.4) and incubated overnight at 4°C.
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The plates were washed with phosphate buffered saline (PBS)-
Tween 20 and blocked with a solution (PBS-5% non-fat dry
milk) for 1 h at room temperature (RT). Next, plasma samples
(1/50) were added to the wells. After 1 h of incubation at RT,
the plates were washed and horseradish peroxidase-
conjugated rabbit anti-human IgA (catalog. No. P0216,
DakoCytomation) was added (1/500) to duplicate wells and
incubated for 1 h at RT. Then the plates were washed, and
substrate solution (TMB, Sigma) was added. After 30 min of
incubation at RT in the dark, the reaction was stopped with 0.3
M sulphuric acid, and the absorbance at 450 nm was
measured (microplate reader UVM340, Asys Hitech GmbH,
Eugendorf, Austria).
9: Statistical analysis
Each plasma sample was analyzed by triplicate and the
mean value calculated. Positive and negative controls (CD-
patients and C-individuals, respectively) and buffer blanks were
included in each assay. An absorbance cutoff value was
defined for each age group. It was calculated using the GP-
patients (mean ± 2 x standard deviation) with the aim of
discriminate, with the higher specificity possible, between that
group and CD-patients. Only samples with an absorbance
value ≥ cutoff value were considered positives. Unpaired, two-
tailed Student’s t-test was applied and p<0.05 was considered
as statistically significant. Specificity [(true negatives / (true
negatives + false positives)) x 100]s and sensitivity [true
positives / (true positives + false negatives)] x 100] were
calculated for each age group.
Table 3. Peptides derived from gliadin 8-mer sequence
supplied by Biomedal S.L for the development and
standardization of the ELISA.
Peptide Sequence
PEP-BIO 1 FPLQPQQPK-BIOTIN
PEP-BIO 2 FPLQPEQPK-BIOTIN
PEP 1 CGG FPLQPQQP GGG FPLQPQQP
PEP 2 CGG FPLQPEPQ GGG FPLQPEQP GGG FPLQPEQP
PEP 3 CGG FPLQPEQP GGG FPLQPEQP
PEP 4 CGG FPLQPEQP
PEP 5 CGG QPFPQPELPFP GGG FPLQPEQP
PEP 6 CGG PEQPYPQP GGG QPFPQPELPFP GGG FPLQPEQP
PEP 7 PALM-GGG FPLQPEQP
PEP 8 PALM-FPLQPEQP GGG FPLQPEQP
PEP 9 PALM-QPFPQPEQPFPQPELPFP GGG FPLQPEQP
PEP 10 Cyclic FPLQPEQP (head to tail)
Two biotynilated peptides (native and deamidated) and ten different combinations
of sequence and terminal modifications.
PALM: Palmitic acid.
doi: 10.1371/journal.pone.0080982.t003
Results
1: Duodenal gliadin-degrading proteases specific from
celiac patients release an 8-mer gliadin peptide
Gliadin zymogram analysis confirmed that the gliadin-
degrading protease pattern was specifically found in the
duodenum of all 4 CD patients irrespectively of their status
(aCD/GFD) or age (adults/children) while remained absent in
protein samples obtained from non-CD pathogenic control
(Figure S1) as previously reported [11]. In order to identify
gliadin peptides specifically released by such enzymes,
fingerprinting was applied to the most intense gliadin-degrading
band obtained from the zymogram matrix (26 kDa) from a
GFD-patient. The fingerprinting profiles did not allow any match
with any known protein. Therefore, a secondary MALDI-TOF
ion-trap MS was applied and 3 peptides (8-, 15- and 18-mer)
were identified (Table 4 and Figure S2).
To determinate the nature of the cleaving points generated in
the 3 peptides resulting from the above analysis, we conducted
a search on the peptidase database MEROPS [15]. As shown
in Table 4, the C-end of the 15-mer peptide and both ends of
the 18-mer peptide were potential cleaving points for trypsin so
they may have been generated by the trypsin digestion applied
during MALDI-TOF analysis. However, the N-end of the 15-mer
peptide and both ends of the 8-mer peptide lack any described
trypsin cleaving point so they did not seem to have been
released during technical processing of the samples but on the
contrary were likely to have been released by the action of the
CD-specific duodenal gliadin-degrading proteases. A second
independent analysis was also performed on the 82 kDa
gliadin-degrading protease obtained from an aCD-patient
revealing again the 8-mer gliadin peptide (Table 4). Since such
peptide was found in two independent experiments and its
cleaving points were likely to be derived from the CD-specific
duodenal gliadin degrading proteases we decided to study it in
depth.
Table 4. Peptides identified by ion-trap mass spectrometry
analysis of the 26 kDa degradation band: 8-mer, 15-mer
and 18-mer; and their alignment with the original sequence
from the proteins ω- and γ-gliadin and LMW glutenin from
which they proceeded.
Peptide Prolamin Sequence alignment
8-mer  FPLQPQQP
 ω-gliadin -S.FPLQPQQP.F-
15-mer  PFIQPSLQQQLNPCK
 γ-gliadin -P.PFIQPSLQQQLNPCK.N-
18-mer  VFLQQQCSPVAMPQSLAR
 LMW-glutenin -K.VFLQQQCSPVAMPQSLAR.S-
In bold, cleaving points that could not had been generated through the technical
process involving trypsin digestion and therefore likely to be derived from biological
protease activities.
doi: 10.1371/journal.pone.0080982.t004
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2: Identification of the 8-mer peptide in proteins from
toxic cereals for celiac patients
The sequence alignment made with the BLASTP program of
the NCBI server [16] revealed several homologous sequences
to the 8-mer gliadin peptide which remained restricted to
prolamin and glutenin proteins from cereals which are toxic to
CD patients like wheat, rye and barley species. None of the 8-
mer homologous sequences were found in non toxic cereals to
CD patients, i.e. rice or maize. A full length copy of the 8-mer
peptide was identified in 12 different species from the true
grasses genera: Hordeum, Triticum, Lophopyrum, Aegilops
 and Secale. The 8-mer was more abundant in prolamins from
wheat (ω-gliadin and ω-secalin in Triticum) with 196 peptides
matched. Results are detailed in Table 5 and 6.
3: The 8-mer peptide overlaps with 3 known gluten T
cell epitopes
We carried out a search for the known CD relevant gluten T
cell epitopes restricted by HLA-DQ molecules [6] in proteins
containing the 8-mer peptide. The 8-mer peptide appeared
overlapped or next to three T-cell epitopes (Table 7), and the
most repeated was QQPFPQQPQ [17] which overlapped in
Table 5. Sequence alignment searches using the BLASTP algorithm v.2.2.20 in NCBI protein database with the 8-mer
(FPLQPQQP) gliadin peptide.
Prolamins Closest relative protein Accession Score Peptides matched
Hordein C-hordein storage protein, partial (Hordeum vulgare) gi|123461 152 1
 B3-hordein (Hordeum vulgare) gi|123459 137 1
 C-hordein (Hordeum vulgare) gi|442524 582 2
 C-hordein (Hordeum vulgare subsp. vulgare) gi|442524 659 3
Glutenin D-type LMW* glutenin subunit (Triticum aestivum) gi|208605344 724 3
γ-gliadin γ-gliadin (Trtiticum aestivum) gi|379319141 223 1
ω-gliadin ω-gliadin storage protein (Triticum aestivum) gi|10444084 489 3
 ω-gliadin partial (Triticum aestivum) gi|224747073 647 3
 ω-gliadin partial (Triticum aestivum) gi|224746065 621 5
 ω-gliadin partial (Triticum aestivum) gi|224747071 716 5
 Putative ω-gliadin (Triticum aestivum) gi|63252971 775 3
 ω-gliadin partial (Triticum aestivum) gi|224747067 799 6
 ω-gliadin partial (Triticum urartu) gi|294998471 483 4
 ω-gliadin partial (Triticum urartu) gi|294998469 647 3
 ω-gliadin partial (Triticum urartu) gi|294998467 685 5
 ω-gliadin partial (Triticum urartu) gi|294998465 679 6
 ω-gliadin partial (Triticum monococcum subsp. aegilopoides) gi|294998463 540 1
 ω-gliadin partial (Triticum monococcum subsp. aegilopoides) gi|294998461 631 1
 ω-gliadin partial (Triticum monococcum) gi|294998449 674 2
 ω-gliadin partial (Triticum monococcum) gi|294998453 645 1
 ω-gliadin partial (Triticum monococcum) gi|294998455 567 2
 ω-gliadin partial (Triticum monococcum) gi|294998457 713 1
 ω-gliadin partial (Triticum monococcum) gi|294998451 647 1
 ω-gliadin partial (Triticum turgidum subsp. paleocolchicum) gi|281398157 678 2
 ω-gliadin partial (Lophopyrum elongatum) gi|224747083 647 1
 ω-gliadin partial (Lophopyrum elongatum) gi|224747089 666 1
 ω-gliadin partial (Lophopyrum elongatum) gi|224747087 656 2
 ω-gliadin partial (Triticum aestivum x Lophopyrum elongatum) gi|224747080 647 1
 ω-gliadin partial (Triticum aestivum x Lophopyrum elongatum) gi|224747075 652 4
 ω-gliadin partial (Triticum aestivum x Lophopyrum elongatum) gi|224747078 703 6
 ω-gliadin (Aegilops markgrafii) gi|410025837 612 2
 ω-gliadin (Aegilops markgrafii) gi|410025835 578 2
 ω-gliadin (Aegilops markgrafii) gi|410025829 668 3
 ω-gliadin (Aegilops markgrafii) gi|410025833 676 3
 ω-gliadin (Aegilops markgrafii) gi|410025831 759 4
 ω-gliadin partial (Aegilops tauschii) gi|373430784 592 1
 ω-gliadin partial (Aegilops tauschii) gi|50313199 781 3
Protein sequences are grouped according to the type of prolamin (hordein, glutenin, γ-gliadin and ω-gliadin) and the number of 8-mer peptide matched in each sequence is
shown. LMW (Low Molecular Weight).
doi: 10.1371/journal.pone.0080982.t005
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34.5% of the 8-mer peptides matched in ω-gliadin, 13.1% in ω-
secalin, 14.3% in hordein and 33.4% in glutenin sequences.
Two more T-cell epitopes were close to the 8-mer peptide
despite not overlapping, QQPQQPFPQ and PFPQPQQPF
[17,18], which were more repeated in ω-secalin.
4: Development and standardization of ELISA based on
the 8-mer peptide
HLA-DQ2 and DQ8 molecules have preference for binding of
negatively charged amino acid residues in certain binding
pockets [19]. In vivo, enzyme tTG mediates deamidation of
Table 6. Sequence alignment searches using the BLASTP algorithm v.2.2.20 in NCBI protein database with the 8-mer
(FPLQPQQP) gliadin peptide.
Prolamins Closest relative protein Accession Score Peptides matched
ω-secalin Putative ω-secalin (Triticum aestivum) gi|226247119 196 1
 Putative ω-secalin (Triticum aestivum) gi|226247117 202 1
 Putative ω-secalin (Triticum aestivum) gi|226247115 286 2
 Putative ω-secalin (Triticum aestivum) gi|226247113 205 2
 Putative ω-secalin (Triticum aestivum) gi|226247111 290 1
 Putative ω-secalin (Triticum aestivum) gi|226247109 315 2
 Putative ω-secalin (Triticum aestivum) gi|226247107 328 1
 Putative ω-secalin (Triticum aestivum) gi|226247105 313 1
 Putative ω-secalin (Triticum aestivum) gi|226247103 327 1
 Putative ω-secalin (Triticum aestivum) gi|226247101 310 1
 Putative ω-secalin (Triticum aestivum) gi|226247099 359 2
 Putative ω-secalin (Triticum aestivum) gi|226247097 289 3
 Putative ω-secalin (Triticum aestivum) gi|226247095 317 4
 Putative ω-secalin (Triticum aestivum) gi|226247093 392 3
 Putative ω-secalin (Triticum aestivum) gi|226247091 334 2
 Putative ω-secalin (Triticum aestivum) gi|225625618 295 2
 Putative ω-secalin (Triticum aestivum) gi|225625624 366 3
 Putative ω-secalin (Triticum aestivum) gi|225625620 399 2
 Putative ω-secalin (Triticum aestivum) gi|225625622 416 3
 Putative ω-secalin (Triticum aestivum) gi|225625614 463 1
 Putative ω-secalin (Triticum aestivum) gi|225625616 444 4
 ω-secalin (Triticum aestivum) gi|229610236 516 2
 ω-secalin (Triticum aestivum) gi|229610230 573 4
 ω-secalin (Triticum aestivum) gi|229610226 700 5
 ω-secalin (Triticum aestivum) gi|229610238 698 4
 ω-secalin (Triticum aestivum) gi|229610234 699 5
 ω-secalin (Triticum aestivum) gi|229610232 577 5
 ω-secalin (Triticum aestivum) gi|229610228 703 6
 Putative ω-secalin (Triticum aestivum) gi|225625626 708 6
 ω-secalin (Secale cereale) gi|2145025 692 4
 Sec1 precursor (Secale cereale) gi|21202 677 6
 ω-secalin (Secale cereale) gi|229610198 661 4
 ω-secalin (Secale cereale) gi|229610196 687 6
 ω-secalin (Secale cereale) gi|229610194 654 5
 ω-secalin (Secale cereale) gi|229610192 685 5
 ω-secalin (Secale cereale) gi|229610190 664 5
 Sec1 precursor (Secale cereale) gi|21204 669 6
 ω-secalin (Triticum aestivum x Secale cereale) gi|229610219 661 6
 ω-secalin (Triticum aestivum x Secale cereale) gi|229610217 700 6
 ω-secalin (Triticum aestivum x Secale cereale) gi|229610215 645 4
 ω-secalin (Secale cereale x Triticum durum) gi|229610210 704 6
 ω-secalin (Secale cereale x Triticum durum) gi|229610208 696 6
 ω-secalin (Secale cereale x Triticum durum) gi|229610206 687 6
 ω-secalin (Secale cereale x Triticum durum) gi|229610204 699 6
Protein sequences from ω-secalin and the number of 8-mer peptide matched in each sequence is shown.
doi: 10.1371/journal.pone.0080982.t006
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some glutamine residues into glutamic acid acquiring a
negative charge and rendering peptides more suitable for
presentation by DQ2&DQ8 molecules [7]. Thus, we studied the
presence in plasma samples from CD patients of IgA Abs
against both the native and deamidated 8-mer peptides. It has
been shown that the targeting of Q residues in peptides is
strongly influenced by the position of C-terminally located P
residues. Whereas a Q residue in the QXP consensus
sequence is targeted by tTG, Q residues in a QP or QXXP
sequence motif are not [20,21]. Therefore, we studied the
effect on the reactivity of the 8-mer peptide after its
deamidation in position 6 (FPLQPEQP).
Two synthetic biotynilated peptides (native and deamidated,
Table 3) were used in streptavidin coated plates to study the
presence of IgA antibodies in plasma samples from CD
patients (Biomedal S.L). The levels of IgA Abs against
deamidated 8-mer peptide in plasma samples from celiac
patients was three fold higher than the one observed in the
same patients with the native 8-mer peptide (results not
shown). The antigen-antibody complex seemed to be stronger
when the deamidated 8-mer peptide was used than with the
native sequence. In order to improve the detection of
antibodies by ELISA, ten different combinations of sequence
and terminal modifications were designed (Table 3) and
containing, all but one, at least one copy of deamidated gliadin
8-mer epitopes (Biomedal S.L). Finally, the combination of two
peptides was selected as the optimum recombinant antigen to
coat the microtiter plates for the standardization of the ELISA.
5: Detection of IgA anti-DGP 8-mer antibodies in
plasma samples from celiac children
The ELISA test designed in this article allowed us to identify
IgA Abs which recognize DGP 8-mer as a specific antigen in
the plasma from CD patients. Having optimized the technique,
we first studied the presence of specific IgA anti-DGP 8-mer
Abs in plasma from celiac children (Table 2, Figure 1 (A)). The
absorbance values (mean ± SEM) at O.D 450 nm obtained for
Table 7. Identification and analysis of the alignment
between the 8-mer peptide and three gluten T-cell epitopes
identified previously.
Prolamins T-cell epitopes Peptides
γ-gliadin QQPQQPFPQ QQP.FPLQPQQP.FPQPQQPQQPFPQ.X
ω-gliadin QQPFPQQPQ QQX.FPLQPQQP.FPQQPQQP
 QQPQQPFPQ QQX.FPLQPQQP.FPQQPQQPFPQ.X
 QQPFPQQPQ QLQQPFPQQPQQP.FPLQPQQP.FP
ω-secalin QQPFPQQPQ QQX.FPLQPQQP.FPQQPQ
 PFPQPQQPF QQX.FPLQPQQP.SPQQPQLPFPQPQQPFVVVV
Hordein QQPFPQQPQ QQP.FPLQPQQP.FPQQPQQPFPQPQQPFR
 PFPQPQQPF QQPFPQPQQP.FPLQPQQP.FP
Glutenin QQPFPQQPQ S.FPLQPQQP.FPQQPQQPFPQP
 QQPQQPFPQ QQPQQPFPQQPQQP.FPLQPQQP.FP
In bold, 8-mer peptide sequence and T-cell epitopes are indicated by underlining.
BLASTP (v 2.2.20) and Merops (v 9.8) databases were used.
doi: 10.1371/journal.pone.0080982.t007
each group of patients were: aCD-patients (n=31) 1.61 ± 0.24,
GFD-patients (n=17) 0.14 ± 0.02, C-individuals (n=10) 0.06 ±
0.003 and GP-patients (n=23) 0.10 ± 0.01. According to the
cutoff value calculated for the pediatric population (0.21),
among aCD-patients (n=31), there were 29 positives and 2
negatives for IgA anti-DGP 8-mer Abs. In the case of GFD-
patients, only 2 children were positives for IgA-8-mer Abs. Very
low levels of IgA anti-DGP 8-mer Abs were detected in 1 out of
23 GP-patients. The remaining 22 GP-patients and all C-
individuals had negative levels for IgA anti-DGP 8-mer Abs.
Comparison of the mean absorbance levels between aCD-
patients and the remainder groups showed significant
differences (p<0.001). IgA anti-DGP 8-mer Abs not only
differentiated between CD patients and non-CD patients, but
also between active celiac patients and those celiac patients
who have initiated a GFD. The modified ELISA method used
for detect IgA anti-DGP 8-mer antibodies showed 94% of
specificity and 93.5% of sensitivity in children.
6: Detection of IgA anti-DGP 8-mer antibodies in
plasma samples from celiac adults
CD is a common disorder in children and adults, and shows
age-related differences at initial diagnosis. Given that IgA anti-
TGt levels correlate both with the degree of villous atrophy and
with the patient’s age [22], we studied if the IgA anti-DGP 8-
mer ELISA test could be also applied to adult patients (Table
2).
Results obtained in the adult population are shown in Figure
1 (B). The absorbance values at O.D 450 nm obtained for each
group were (mean ± SEM): aCD-patients (n=16) 1.19 ± 0.28,
GFD-patients (n=12) 0.31± 0.03, C-individuals (n=27) 0.17 ±
0.01; and GP-patients (n=46) 0.26 ± 0.01. According to the
cutoff value calculated for the adult population (0.5), among the
group of aCD- patients (n=16), there were 13 positives and 3
negatives for IgA anti-DGP 8-mer Abs. All GFD-patients (n=12)
had negative levels of antibodies, except one. IgA anti-DGP 8-
mer Abs were not detected in any of the non-celiac patients.
When mean absorbance levels obtained by aCD-patients
and the remainder groups were compared, significant
differences were obtained (p<0.001). The ELISA test showed a
specificity of 98.8% and a sensitivity of 81.3% in adult
population.
Discussion
We have previously described a CD-specific duodenal
gliadin-degrading pattern with seven proteases with molecular
weight’s ranging from 20 kDa to 92 kDa [11]. In this work we
describe for the first time to our knowledge a new gliadin-
derived 8-mer peptide (FPLQPQQP) released after gliadin
digestion by duodenal CD-specific proteases. In addition, it
remained restricted to prolamin and glutenin proteins from toxic
cereals to CD patients (wheat, barley and rye). Among the
more than 250 homologous sequences to the 8-mer peptide
matched most of them was expressed in ω-prolamins (gliadin
and secalin). To study if the 8-mer peptide could be found in
already described toxic peptides for CD patients, we carried out
a search for the known CD relevant gluten T-cell epitopes
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Figure 1.  Detection of IgA anti-DGP 8-mer antibodies in plasma samples from children (A) and adults (B).  Study groups:
active celiac disease (aCD-patients), on a gluten-free diet (GFD-patients), healthy controls (C-individuals) and other gastrointestinal
pathology (GP-patients). Each point represents the mean absorbance value of one patient at O.D 450 nm. According to the cutoff
value (0.21 in children and 0.5 in adults, pointed line), patients with a higher absorbance value were considered positive for IgA anti-
DGP 8-mer Abs, while those with lower absorbance values were considered negative. * p<0.05, ** p<0.01 and *** p<0.001
(Unpaired, two-tailed Student’s t-test). A- Among pediatric population 90.6% of aCD, 10.5% of GFD and 4.3% of GP-patients were
positive for IgA anti-DGP 8-mer antibodies, and 9.4% of aCD-patients, 89.5% of GFD-patients, 100% of C-individuals and 95.7% of
GP-patients were negative. B- In adult population, 18.7% of aCD, 100% of GFD-patients, C-individuals and GP-patients were
positive for IgA anti-DGP 8-mer, while 18.7% of aCD and 100% of GFD-, C- and GP-patients were negative.
doi: 10.1371/journal.pone.0080982.g001
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restricted by HLA-DQ molecules [6]. Since several HLA-DQ
restricted gluten T-cell epitopes overlapped or were close to
the 8-mer peptide, we wondered if IgA antibodies against the 8-
mer peptide could be found in the plasma from CD patients.
The first ELISA assays in which native and deamidated 8-
mer peptide were compared, showed an increase in the IgA
anti 8-mer levels in CD patients when the peptide was
deamidated in position 6. The increase in the reactivity of
gliadin peptides in CD has been observed in several studies of
native and deamidated peptides [23,24], and the effect of
deamidation has been confirmed in the induction of a Th2
response in a mice model [25]. For that reason, we designed
different peptides containing at least one copy of the DGP 8-
mer and combined with terminal modifications (Biomedal S.L)
in order to select those more effective in the cover of the plate
and in the binding to the antibodies. Finally, the combination of
two peptides was selected as the optimum recombinant
antigen to develop the assay which allowed as to detect IgA
anti-DGP 8-mer in CD-patients.
Among pediatric population, levels of IgA anti-DGP 8-mer
Abs were negative only in 2 aCD-patients (aCD-30 and aCD-31
in Table 8). A possible explanation for one of these cases is
that the patient number 31 has a celiac sister so it is possible
that he was already following (at least partially) either a GFD or
a low-gluten containing diet as most of close relatives of CD
patients do. Regarding GFD-patients, IgA anti-DGP 8-mer Abs
were positive only in 2 of 17 children. One of them (GFD-32 in
Table 9) turned out to be a case of not response to the gluten-
free diet in addition to suffering prolonged diarrhea and also
having negative IgA anti-tTG levels. The other child on a GFD
with positive IgA anti-DGP 8-mer levels (GFD-33 in Table 9),
had IgA anti-tTG levels one unit above the cutoff value, and 6
months later, IgA anti-tTG plasma levels became negative.
Ten children had positive levels of IgA anti-tTG despite being
on a GFD and having clinical recovery. However, all of them
were negative for IgA anti-DGP 8-mer Abs suggesting the
possible application of IgA anti-DGP 8-mer antibodies as a
marker of GFD compliance in children. Nevertheless, further
studies are required to confirm this point, including an
assessment of the patients and a direct and controlled
comparison of the tTG enzyme and DGP 8-mer peptide IgA
antibodies, with direct controls of GFD compliance by fecal
detection of gluten peptides [26].
Although IgA anti-tTG antibodies have been proposed as
markers of GFD compliance, their effectiveness is still not clear
since they have been reported both well [27] or poorly [28]
correlated with dietary transgressions. The normalization of IgA
anti-tTG levels occurs, approximately, after 6 months on a strict
GFD. Nevertheless, IgA anti-DGP 8-mer Abs were not detected
in a child after a month on a GFD, while he was positive for IgA
ant-tTG. In agreement with our data, Comino et al [26]
estimated the time of total gluten toxic-peptide excretion to be
between 2 and 6 days and the biological half-live for IgA
antibodies in human plasma has been calculated in 5.9 and 4.5
days for IgA1 and IgA2 subclasses respectively [29].
Specificity is the critical parameter to discriminate CD from
other gastrointestinal pathologies, and sensitivity is crucial for
finding new patients. Among the 23 GP-patients studied, only
one patient, who was son of a CD woman, was positive for IgA
anti-DGP 8-mer test. According to a recent report published in
2012 by the ESPGHAN [13] and other studies of antibodies
against DGP [30,31], the specificity is ranged between 86.3%
and 93.1%, while sensitivity is in the range of 80.7% to 95.1%.
Since our results in pediatric population were similar to those
observed in other DGP studies, we next wondered if our ELISA
test could also be applied to the adult population where CD is
more frequently diagnosed in older population (20% of the
Table 8. Clinical data from active celiac patients (n=31)
from the pediatric population (n=48).
Sample Sex  Age 
HLA
DQ2/DQ8
IgA anti-
tTG  
IgA anti-
DGP 8-mer
Atrophy grade at
diagnosis (Marsh
criteria)
aCD-1 M 2 + + + III
aCD-2 F 2 + + + III
aCD-3 F 3 + + + III
aCD-4 F 1 + + + III
aCD-5 M 1 + + + II
aCD-6 F 3 + + + III
aCD-7 M 1 + + + N.D
aCD-8 F 2 + + + N.D
aCD-9 F 3 + + + III
aCD-10 M 2 + + + III
aCD-11 M 2 + + + III
aCD-12 F 2 + + + M.M
aCD-13 F 3 + + + III
aCD-14 F 6 + + + III
aCD-15 F 1 + + + N.D
aCD-16 F 2 + + + III
aCD-17 F 9 + + + III
aCD-18 F 2 + + + III
aCD-19 M 8 + + + N.D
aCD-20 F 2 + + + N.D
aCD-21 M 3 + + + III
aCD-22 F 2 + + + III
aCD-23 F 3 + + + III
aCD-24 F 3 + + + III
aCD-25 F 2 + + + III
aCD-26 F 10 + + + III
aCD-27 F 10 + + + I
aCD-28 F 1 + + + III
aCD-29 M 11 + + + III
aCD-30 M 1 + + - III
aCD-31 F 9 + + - III
Table shows the following information: sex (M: male and F: female), age (from 1 to
12 years), HLA DQ2/DQ8, IgA anti-tTG, IgA anti-DGP 8-mer and Marsh scale of
the severity of lesion at diagnosis (from Marsh I to Marsh III). N.D (Not determined)
and M.M (mild mucosal alterations).
doi: 10.1371/journal.pone.0080982.t008
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celiac adults are older than 65 years). Therefore, classical
gastrointestinal symptoms characteristics of CD are usually
accompanied by other manifestations and pathologies usually
linked with the age including liver cirrhosis, inflammatory bowel
disease and diabetes mellitus, which have been related with
CD in several studies [32–36]. Since CD diagnosis in adults is
getting more complicated and false positive reactions for IgA
anti-tTG have been reported we also studied 46 plasma
samples from adult non-celiac patients but with other
gastrointestinal pathology. All of them were negative for IgA
anti-DGP 8-mer while some of them had positive levels of IgA
anti-tTG revealing therefore a specificity of 100% in such
cohort.
The highest absorbance values in pediatric population
(Figure 1 (A)) were almost 4 fold over those observed in the
adult one (Figure 1 (B)). However IgA anti-DGP 8-mer
antibodies could provide an additional degree of specificity in
both populations, compared to other serological markers, due
to the following reasons: tissue transglutaminase enzyme is
expressed in a constitutive manner in everyone [37] because of
its functions in apoptosis and cellular differentiation and anti-
tTG antibodies may persist independently of the GFD
compliance or could be generated in other pathologies. In
Table 9. Clinical data from celiac patients on a gluten-free
diet (n=17) from the pediatric population (n=48).
Sample Sex  Age 
HLA DQ2/
DQ8   
IgA anti-
tTG  
IgA anti-
DGP 8-
mer
Atrophy grade
at diagnosis
(Marsh
criteria)  
Months on
GFD
GFD-32 F 10 + - + III N.R
GFD-33 F 7 + + + III 4
GFD-34 F 6 + - - III 4
GFD-35 F 2 + + - N.D 1.5
GFD-36 M 4 + + - III 3
GFD-37 F 2 + - - N.D 6
GFD-38 F 3 + + - III 3
GFD-39 M 4 + + - III 4
GFD-40 F 2 + - - N.D 10
GFD-41 F 2 + - - N.D 6
GFD-42 M 5 + + - III 3
GFD-43 M 2 + - - III 2
GFD-44 F 3 + + - II 3
GFD-45 M 1 + + - III 12
GFD-46 M 12 + + - N.D 5
GFD-47 F 11 + + - N.D 7
GFD-48 M 2 + + - N.D 1
Table shows the following information: sex (M: male and F: female), age (from 1 to
12 years), HLA DQ2/DQ8, IgA anti-tTG, IgA anti-DGP 8-mer and Marsh scale of
the severity of lesion at diagnosis (from Marsh I to Marsh III). N.D (Not determined)
and M.M (mild mucosal alterations). The time on GFD is shown in months, except
one patient who did not response to the GFD (N.R).
doi: 10.1371/journal.pone.0080982.t009
addition, DGP usually are derived from whole gluten digested
with commercial enzymes like pepsin, trypsin, chymotrypsin,
elastase and carboxypeptidase and subsequently modified with
TG2 [20]. On the other hand, the 8-mer peptide is generated by
specific duodenal proteases of celiac patients.
Conclusion
In this study we have identified, for the first time to our
knowledge plasma CD-specific IgA Abs that recognize as
specific antigen a novel deamidated gliadin peptide
(FPLQPEQP), derived from an 8-mer peptide generated during
duodenal degradation of gliadin by CD-specific duodenal
proteases. The native peptide (FPLQPQQP) remained
restricted to prolamin and glutenin proteins from toxic cereals
to CD patients and was particularly expressed in ω-prolamins.
The 8-mer peptide overlapped with a previously identified
gluten T cell epitope and its ability to develop a humoral
immune response in vivo in CD patients was confirmed by the
detection of IgA anti-DGP 8-mer Abs in plasma samples from
those patients.
The DGP 8-mer could be used as a novel specific CD
antigen for the diagnosis of CD and monitoring of the
compliance of GFD. We have designed an ELISA test which
detects IgA anti-DGP 8-mer Abs in plasma samples from CD-
patients with a high specificity (94% in children and 98.8% in
adults) and sensitivity (93.5% in children and 81.3% in adults).
Future studies with larger number of samples and additional
relevant data (i.e. use of novel tools for GFD compliance) will
assess the full potential of the novel diagnostic tool for celiac
diagnosis and management.
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